The FY24 ARP Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals. Applications are strongly encouraged to address one of the FY24 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in ASD. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.
Research funded by the FY24 ARP should be responsive to the needs of people with ASD, their families, and/or caregivers. Researchers are therefore encouraged to establish and utilize effective collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research.
CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women’s health.
Deadlines:
• Required Pre-Application Deadline: May 16, 2024
• Invitation to Submit an Application: June 2024
• Application Submission Deadline: Aug 15, 2024
To meet the intent of the funding opportunity the ARP encourages applications that address critical needs of the ASD community in one or more of the FY24 ARP Idea Development Award Areas of Interest:
• Assessment of novel therapeutics using valid preclinical models
• Create tools and strategies to increase the speed with which evidence-based practices are deployed in community-based settings
• Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
• Development of health care provider-focused training or tools to improve health care delivery for Autistic individuals across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
• Environmental risk factors
• (New for FY24) Factors impacting quality of life for current and former military families
• Factors promoting success in key transitions to independence for individuals living with ASD
• Improve diagnosis across the life span
• Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions
• Mechanisms of heterogeneous clinical expression of ASD
• Mechanisms underlying conditions co-occurring with ASD (e.g., pain, sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, and seizures)
• Mechanisms underlying sex differences in ASD (i.e., prevalence, biological mechanisms, phenotypic expression, core and comorbid syndrome expression and outcomes, developmental trajectories, diagnosis, and treatment response)
• Tests of implementation strategies to increase use of evidence-based practices
Investigators at or above the level of Assistant Professor (or equivalent) may be named by the organization as the PI on the application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY24 ARP IDA should not exceed $550,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.